Dermatological Drug Development — A Review of Some Important Issues

  • John R. Gibson
Conference paper
Part of the NATO ASI Series book series (NSSA, volume 181)


In this chapter, a view of the skin from a drug developer’s perspective will be presented and a variety of issues pertinent to dermato-logical therapeutics will be discussed. The author is an experienced pharmaceutical physician who practises as a clinical dermatologist and is therefore well placed to provide a commentary on these subjects but will, naturally, be strongly influenced by his background.


Atopic Eczema Stratum Corneum Percutaneous Absorption Penetration Enhancer Chronic Idiopathic Urticaria 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Allenby, C.F., and Sparkes, C.G., 1981, Halogenation and topical corticosteroids: a comparison between the 17-butyrate esters of hydrocortisone and clobetasone in ointment bases. Br. J. Dermatol., 104:179–183.PubMedCrossRefGoogle Scholar
  2. Anderson, V., 1976, Over-the-counter topical antibiotic products: data on safety and efficacy, Int. J. Dermatol., 15(Suppl.):1–118.PubMedGoogle Scholar
  3. Baker, B. S., Griffiths, C. E. M., Lambert, S., Powles, A. V., Leonard, J. N., Valdimarsson, H., and Fry, L., 1987, The effects of cyclosporin A on T lymphocyte and dendritic cell sub-populations in psoriasis, Br. J. Dermatol., 116: 503–510.PubMedCrossRefGoogle Scholar
  4. Baker, H., 1976, Corticosteroids and pustular psoriasis. Br. J. Dermatol.. 94(Suppl 12):83–88.PubMedCrossRefGoogle Scholar
  5. Barrett, K. E., and Metcalfe, D. D., 1984, Mast cell heterogeneity: evidence and implications, J. Clin. Immunol., 4:253–261.PubMedCrossRefGoogle Scholar
  6. Barry, B.W., 1983, “Dermatological formulations: percutaneous absorption.” Marcel Dekker, Inc, New York.Google Scholar
  7. Beveridge, G. W., Fairburn, E., Finn, O.A., Scott, O. L. S., Stewart, T. W., and Summerly, R., 1977, A comparison of nystatin cream with nystatin/triamcinolone acetonide combination cream in the treatment of candidal inflammation of the flexures, Curr. Med. Res. Opin., 4:584–587.PubMedCrossRefGoogle Scholar
  8. Blichmann, C. W., and Serup, J., 1987, Reproducibility and variability of transepidermal water loss measurement. Studies on the Servo Med evaporimeter, Acta Derm. Venereol.(Stockh.). 67: 206–210.Google Scholar
  9. Bunney, M. H., 1982, “Viral warts: their biology and treatment”, Oxford University Press, Oxford.Google Scholar
  10. Burton, J. L., Rook, A., and Wilkinson, D. S., 1986, Eczema, lichen simplex, erythroderma, and prurigo, in: “Textbook of dermatology”, 4th edn., Rook, A., Wilkinson, D. S., Ebling, F. J. G., Champion, R. H., and Burton, J. L., eds., Blackwell Scientific Publications, Oxford.Google Scholar
  11. Busse, M.J., 1978, Dangers of dilution of topical steroids, Pharm. J., 220:25–26.Google Scholar
  12. Camp, R.D.R., and Greaves, M.W., 1987, Inflammatory mediators in the skin, Br. Med. Bull., 43:401–414.PubMedGoogle Scholar
  13. Clement, M., and Du Vivier, A., 1985, Corticosteroids — DNA synthesis suppression methods, in: “Models in Dermatology”, Vol. 2., Maibach, H.I., and Lowe, N.J., eds., Karger, Basel.Google Scholar
  14. Cornell, R.C., and Stoughton, R.B., 1985, Correlation of the vasoconstriction assay and clinical activity in psoriasis, Arch. Dermatol., 121:63–67.PubMedCrossRefGoogle Scholar
  15. Cunningham, F. M., and Camp, R. D. R., 1987, New assays for inflammatory mediators in skin diseases, in: “Models in dermatology”, Vol. 3., Maibach, H. I., and Lowe, N. J., eds., Karger, Basel.Google Scholar
  16. Dahl, M. V., 1983, Staphylococcus aureus and atopic dermatitis, Arch. Dermatol., 119:840–846.PubMedCrossRefGoogle Scholar
  17. Dawson, B., Follenfant, R. L., Higgs, G. A., Schneider, C., and Gibson, J. R., 1985, The effect of BW 540C, a novel anti-inflammatory agent, on ultraviolet-induced physical and histological changes in guinea-pig skin, Br. J. Dermatol., 113(Suppl.28): 137–140.PubMedCrossRefGoogle Scholar
  18. Delforno, C., Holt, P. J. A., and Marks, R., 1978, Corticosteroid effect on epidermal cell size, Br. J. Dermatol., 98:619–623.PubMedCrossRefGoogle Scholar
  19. Dobson, R. L., Leyden, J. J., Noble, W. C., and Price, J. D., 1985, eds., Bactroban (mupirocin), Excerpta Medica, Amsterdam.Google Scholar
  20. Doherty, V., Sylvester, D. G. H., Kennedy, C. T. C., Harvey, S. G., Calthrop, J. G., and Gibson, J. R., 1989, Treatment of itching in atopic eczema with antihistamines with a low sedative profile, Br. Med. J., 298:96.CrossRefGoogle Scholar
  21. Dorsky, D. I., and Crumpacker, C. S., 1987, Drugs five years later: acyclovir, Ann. Intern. Med., 107: 859–874.PubMedGoogle Scholar
  22. Durant, S., Duval, D., and Homo-Delarche, F., 1986, Factors involved in the control of fibroblast proliferation by glucocorticoids: a review, Endocr. Rev., 7:254–269.PubMedCrossRefGoogle Scholar
  23. Du Vivier, A,, and Stoughton, R. B., 1976, Acute tolerance to effects of topical glucocorticosteroids, Br. J. Dermatol., 94(Suppl 12):25–32.PubMedCrossRefGoogle Scholar
  24. Dykes, P. J., and Marks, R., 1979, An appraisal of the methods used in the assessment of atrophy from topical corticosteroids, Br. J. Dermatol., 101:599–609.PubMedCrossRefGoogle Scholar
  25. Ebling, F. J. G., and Cunliffe, W. J., 1986, The sebaceous glands, in: “Textbook of dermatology”, 4th edn., Rook, A., Wilkinson, D. S., Ebling, F. J. G., Champion, R. H., and Burton, J. L., eds., Blackwell Scientific Publications, Oxford.Google Scholar
  26. Elias, P. M., Cooper, E. R., Kore, A., and Brown, B.E., 1981, Percutaneous transport in relation to stratum corneum structure and lipid composition, J. Invest. Dermatol., 76:297–301.PubMedCrossRefGoogle Scholar
  27. Elias, P.M., 1987, The special role of the stratum corneum, in: “Dermatology in general medicine”, 3rd edn., Fitzpatrick, T. B., Eisen, A. Z., Wolff, K., Freedberg, I. M., and Austen, K.F., eds., McGraw-Hill Book Company, New York.Google Scholar
  28. Ellis, C. N., Gorsulowsky, D. C., Hamilton, T. A., Billings, J. K., Brown, M. D., Headington, J. T., Cooper, K. D., Baadsgaard, O., Duell, E. A., Annesley, T. M., Turcotte, J. G., and Voorhees, J. J., 1986, Cyclosporine improves psoriasis in a double-blind study, J. Am. Med. Assoc., 256: 3110–3116.CrossRefGoogle Scholar
  29. Ellis, C. N., and Voorhees, J. J., 1987, Etretinate therapy, J. Am. Acad., Dermatol., 16: 267–291.CrossRefGoogle Scholar
  30. Ford, G. P., Farr, P. M., Ive, F. A., and Shuster, S., 1984, The response of seborrhoeic dermatitis to ketoconazole, Br. J. Dermatol., 111: 603–607.PubMedCrossRefGoogle Scholar
  31. Franz, T. J., 1983, Kinetics of cutaneous drug penetration, Int. J. Dermatol., 22:499–505.PubMedCrossRefGoogle Scholar
  32. Garden, J. M., Freinkel, R. K., 1986, Systemic absorption of topical steroids, Arch. Dermatol., 122:1007–1010.PubMedCrossRefGoogle Scholar
  33. Gibson, J. R., Darley, C., Kirsch, J., Saihan, E. M., and Neild, V. S., 1982, The dilution of proprietary corticosteroid ointments — an attempt to evaluate relative clinical potencies, Br. J. Dermatol., 106:445–448.PubMedCrossRefGoogle Scholar
  34. Gibson, J. R., Kirsch, J., Darley, C. R., and Burke, C. A., 1983a, An attempt to evaluate the relative clinical potencies of various diluted and undiluted proprietary corticosteroid preparations. Clin. Exp. Dermatol., 8:489–493.CrossRefGoogle Scholar
  35. Gibson, J. R., Kirsch, J. M., Darley, C. R., Harvey, S. G., and Burke, C. A., 1983b, The effect on vasoconstrictor potency of combining corticosteroid ointments with coal tar preparations, Br. J. Dermatol., 109(Suppl 24):47–48 (abstract).CrossRefGoogle Scholar
  36. Gibson, J. R., Kirsch, J. M., Darley, C. R., Harvey, S. G., Burke, C. A. and Hanson, M. E., 1984, An assessment of the relationship between vasoconstrictor assay findings, clinical efficacy and skin thinning effects of a variety of undiluted and diluted corticosteroid preparations, Br. J. Dermatol., 111(Suppl 27):204–212.PubMedCrossRefGoogle Scholar
  37. Gibson, J. R., 1985, Predicting the clinical potency of topical corticosteroids, Clin. Exp. Dermatol., 10: 403–404.CrossRefGoogle Scholar
  38. Gibson, J. R., 1987, The use of antihistamines with a low sedative potential in the treatment of the itching of atopic eczema, Clin. Exp. Dermatol., 12:469–470.PubMedCrossRefGoogle Scholar
  39. Gibson, J. R., Hough, J. E., Marks, P., and Webster, A., 1987, Effect of concentration on the clinical potency of corticosteroid ointment formulations, in: “Pharmacology and the skin”, Vol. 1., Shroot, B., and Schaefer, H., eds, Karger, Basel.Google Scholar
  40. Gibson, J. R., 1988, The treatment of viral warts with interferons, J. Antimicrob. Chemother., 21:391–393.PubMedCrossRefGoogle Scholar
  41. Gibson, J. R., and Manna, V. K., in press, Drugs for eczema, in.: “Human drug evaluation”, O’Grady, J., and Linet, O., eds, MacMillan Press, London.Google Scholar
  42. Gibson, J. R., Manna, V. K., and Salisbury, J., in press, Acrivastine — a review of its dermatopharmacology and clinical activity, J. Int. Med. Res.Google Scholar
  43. Goldfarb, J., Crenshaw, D., O’Horo, J., Lemon, E., and Blumer, J. L., 1988, Randomised clinical trial of topical mupirocin versus oral erythromycin for impetigo, Antimicrob. Agents Chemother., 32:1780–1783.PubMedGoogle Scholar
  44. Goldfarb, M. T., Ellis, C. N., and Voorhees, J. J., 1987, Retinoids in dermatology, Mayo Clin. Proc., 62: 1161–1164.PubMedGoogle Scholar
  45. Goldsmith, L. A., 1983, ed., “Biochemistry and physiology of the skin”, Oxford University Press, New York.Google Scholar
  46. Gratton, D., 1987, Topical mupirocin versus oral erythromycin in the treatment of primary and secondary skin infections, Int. J. Dermatol., 26:472–473.PubMedCrossRefGoogle Scholar
  47. Greaves, M. W., 1988, Cutaneous and pharmacological responses to nonsteroidal anti-inflammatories, Skin Pharmacol., 1:44.Google Scholar
  48. Green, C. A., Farr, P. M., and Shuster, S., 1987, Treatment of seborrhoeic dermatitis with ketoconazole: II. Response of seborrhoeic dermatitis of the face, scalp and trunk to topical ketoconazole, Br. J. Dermatol., 116:217–221.PubMedCrossRefGoogle Scholar
  49. Griffiths, C. E. M., Powles, A. V., McFadden, J., Baker, B. S., Valdimarsson, H., and Fry, L., 1989, Long-term cyclosporin for psoriasis, Br. J. Dermatol., 120: 253–260.PubMedCrossRefGoogle Scholar
  50. Griffiths, W. A. D., Ive, F. A., and Wilkinson, J. D., 1986, Topical therapy, in: “Textbook of dermatology”, 4th edn., Rook, A., Wilkinson, D. S., Ebling, F. J. G., Champion, R. H., and Burton, J. L., eds., Blackwell Scientific Publications, Oxford.Google Scholar
  51. Gupta, A. K., and Anderson, T. F., 1987, Psoralen photochemotherapy, J. Am. Acad. Dermatol., 17: 703–734.PubMedCrossRefGoogle Scholar
  52. Guy, R. H., Tur, E., and Maibach, H. I., 1985, Optical techniques for monitoring cutaneous microcirculation. Recent applications, Int. J. Dermatol., 24:88–94.PubMedCrossRefGoogle Scholar
  53. Guy, R. H., Bucks, D. A. W., McMaster, J. R., Villaflor, D. A., Roskos, K. V., Hinz, R. S., and Maibach, H. I., 1987, Kinetics of drug absorption across human skin in vivo. Developments in methodology, in: “Pharmacology and the skin”, Vol. 1., Shroot, B., and Schaefer, H., eds., Karger, Basel.Google Scholar
  54. Haleblian, J. K., 1976, Bioassays used in development of topical dosage forms, J. Pharm. Sci., 65:1417–1436.PubMedCrossRefGoogle Scholar
  55. Harst, L. C. A. v. d., Jonge, H. de, Pot, F., and Polano, M. K., 1982, Comparison of two application schedules for clobetasol 17 propionate, Acta Derm. Venereol.(Stockh.). 62:270–273.Google Scholar
  56. Hay, R., 1982, Ketoconazole, Br. Med. J., 285: 584–585.CrossRefGoogle Scholar
  57. Illel, B., and Schaefer, H., 1988, Transfollicular percutaneous absorption. Skin model for quantitative studies, Acta Derm. Venereol. (Stockh.). 68: 427–430.Google Scholar
  58. Jarrett, A., 1973–1986, ed., “The physiology and pathophysiology of the skin”, Vols. 1–9, Academic Press, London.Google Scholar
  59. Jones, D. H., King, K., Miller, A. J., and Cunliffe, W. J., 1983, A dose-response study of 13-cis-retinoic acid in acne vulgaris, Br. J. Dermatol., 108: 333–343.PubMedCrossRefGoogle Scholar
  60. Juhlin, L., Gibson, J. R., Harvey, S. G., and Huson, L. W., 1987, Acrivastine versus clemastine in the treatment of chronic idiopathic urticaria. A double-blind, placebo-controlled study. Int. J. Dermatol., 26: 653–654.PubMedCrossRefGoogle Scholar
  61. Kirsch, J., Gibson, J. R., Darley, C. R., and Burke, C. A., 1983, A comparison of the potencies of several diluted and undiluted corticosteroid preparations using the vasconstrictor assay, Dermatologica, 167:138–141.PubMedCrossRefGoogle Scholar
  62. Kobza Black, A., Barr, R. M., Wong, E., Brain, S., Greaves, M. W., Dickinson, R., Shroot, B., and Hensby, C. N., 1985, Lipoxygenase products of arachidonic acid in human inflamed skin, Br. J. Clin. Pharmacol., 20:185–190.Google Scholar
  63. Kragballe, K., and Herlin, T., 1983, Benoxaprofen improves psoriasis. A double-blind study, Arch. Dermatol., 119: 548–552.PubMedCrossRefGoogle Scholar
  64. Kragballe, K., Beck, H. I., and Sogaard, H., 1988, Improvement of psoriasis by topical vitamin D3 analogue (MC 903) in a double-blind study, Br. J. Dermatol., 119: 223–230.PubMedCrossRefGoogle Scholar
  65. Krause, L., and Shuster, S., 1983, Mechanism of action of antipruritic drugs, Br. Med. J., 287:1199–1200.CrossRefGoogle Scholar
  66. Lake-Bakaar, G., Scheuer, P. J., and Sherlock, S., 1987, Hepatic reactions associated with ketoconazole in the United Kingdom, Br. Med. J., 294: 419–422.CrossRefGoogle Scholar
  67. Lee, T. D. G., Swieter, M., Bienenstock, J., and Befus, A. D., 1985, Heterogeneity in mast cell populations, Clin. Immunol. Rev., 4:143–199.PubMedGoogle Scholar
  68. Leigh, I. M., Purkis, P. E., Navsaria, H. A., and Phillips, T. J., 1987, Treatment of chronic venous ulcers with sheets of cultured allogenic keratinocytes, Br. J. Dermatol., 117: 591–597.PubMedCrossRefGoogle Scholar
  69. Lever, W. F., and Schaumburg-Lever, G., 1983, “Histopathology of the skin”, 6th edn., J. B. Lippincott Company, Philadelphia.Google Scholar
  70. Leyden, J. J., and Kligman, A. M., 1977, The case for steroid-antibiotic combinations, Br. J. Dermatol., 96:179–187.PubMedCrossRefGoogle Scholar
  71. Leyden, J. J., and Kligman, A. M., 1978, Rationale for topical antibiotics, Cutis. 22:514–527.Google Scholar
  72. Leyden, J. J., and Bartelt, N. M., 1987, Comparison of topical antibiotic ointments, a wound protectant, and antiseptics for the treatment of human blister wounds contaminated with Staphylococcus aureus, J. Fam. Pract., 24:601–604.PubMedGoogle Scholar
  73. Lineaweaver, W., Howard, R., Soucy, D., McMorris, S., Freeman, J., Crain, C., Robertson, J., and Rumley, T., 1985, Topical antimicrobial toxicity, Arch. Surg., 120:267–270.PubMedCrossRefGoogle Scholar
  74. Maibach, H. I., 1976, In vivo percutaneous penetration of corticoids in man and unresolved problems in their efficacy, Dermatologica.152(Suppl 1):11–25.PubMedCrossRefGoogle Scholar
  75. Manku, M. S., Horrobin, D. F., Morse, N. L., Wright, S., and Burton, J. L., 1984, Essential fatty acids in the plasma phospholipids of patients with atopic eczema, Br. J. Dermatol., 110: 643–648.PubMedCrossRefGoogle Scholar
  76. Marks, R., and Williams, K., 1976, The action of topical corticosteroids on the epidermal cell cycle, in: “Mechanisms of topical corticosteroid activity”, Wilson, L. C., and Marks, R., eds., Churchill Livingstone, Edinburgh.Google Scholar
  77. McLinn, S., 1988, Topical mupirocin vs. systemic erythromycin treatment for pyoderma, Pediatr. Infect. Dis., 7:785–790.Google Scholar
  78. Mobacken, H., and Wengstrom, C., 1974, Interference with healing of rat skin incisions treated with Chlorhexidine, Acta Derm. Venereol. (Stockh.), 54:29–34.Google Scholar
  79. Morison, W. L., 1987, Etretinate and psoriasis, Arch. Dermatol., 123: 879–881.PubMedCrossRefGoogle Scholar
  80. Munro, D. D., 1973, Azathioprine in psoriasis, Proc. R. Soc. Med., 66: 747–748.PubMedGoogle Scholar
  81. Munro, D. D., 1976, The effect of percutaneously absorbed steroids on hypothalamic-pituitary-adrenal function after intensive use in in-patients, Br. J. Dermatol., 94(Suppl 12):67–76.PubMedCrossRefGoogle Scholar
  82. Munro, D. D., and Pringle, W. M., 1976, Psoriasis — its response to dithranol and clobetasol propionate: a comparative study, in: “Mechanisms of topical corticosteroid activity”, Wilson, L. C., and Marks, R., eds., Churchill Livingstone, Edinburgh.Google Scholar
  83. Neittaanmaki, H., Fraki, J. E., and Gibson, J. R., 1988, Comparison of the new antihistamine acrivastine (BW 825C) versus cyproheptadine in the treatment of idiopathic cold urticaria, Dermatologica. 177: 98–103.PubMedCrossRefGoogle Scholar
  84. Niedner, R., and Schopf, E., 1986, Inhibition of wound healing by antiseptics, Br. J. Dermatol., 115(Suppl.31):41–44.PubMedCrossRefGoogle Scholar
  85. Orfanos, C. E., Ehlert, R., and Gollnick, H., 1987, The retinoids. A review of their clinical pharmacology and therapeutic use, Drugs. 34:459–503.PubMedCrossRefGoogle Scholar
  86. Palestine, A. G., Nussenblatt, R. B., and Chan, C.-C., 1984, Side effects of systemic cyclosporine in patients not undergoing transplantation, Am. J. Med., 77:652–656.PubMedCrossRefGoogle Scholar
  87. Parrish, J. A., Fitzpatrick, T. B., Tanenbaum, L., and Pathak, M. A., 1974, Photo chemo therapy of psoriasis with oral methoxsalen and longwave ultraviolet light, N. Engl. J. Med., 291: 1207–1211.PubMedCrossRefGoogle Scholar
  88. Pearce, F. L., 1983, Mast cell heterogeneity, Trends Pharmacol. Sci., 4: 165–167.CrossRefGoogle Scholar
  89. Phillipps, G. H., 1976, Locally active corticosteroids: structure-activity relationships, in: “Mechanisms of topical corticosteroid activity”, Wilson, L. C., and Marks, R., eds., Churchill Livings tone, Edinburgh.Google Scholar
  90. Prasad, A. B., 1986, Topical corticosteroids, in: “British National Formulary”, No.11. British Medical Association and The Pharmaceutical Press, London.Google Scholar
  91. Reichman, R. C., Micha, J. P., Week, P. K., Bonnez, W., Wold, D., Whisnant, J. K., Mounts, P., Trofatter, K. F., Kucera, P., and Gall, S. A., 1988, Interferon alpha-nl (Wellferon) for refractory genital warts: efficacy and tolerance of low dose systemic therapy, Antiviral Res., 10: 41–57.PubMedCrossRefGoogle Scholar
  92. Richards, D. M., Brogden, R. N., Heel, R. C., Speight, T. M., and Avery, G. S., 1984, Astemizole — a review of its pharmacodynamic properties and therapeutic efficacy, Drugs. 28: 38–61.PubMedCrossRefGoogle Scholar
  93. Robertson, D. B., and Maibach, H. I., 1982, Topical corticosteroids, Int. J. Dermatol., 21:59–67.PubMedCrossRefGoogle Scholar
  94. Rook, A., Wilkinson, D. S., Ebling, F. J. G., Champion, R. H., and Burton, J. L., 1986a, eds., “Textbook of dermatology”, 4th edn., Blackwell Scientific Publications, Oxford.Google Scholar
  95. Rook, A., Savin, J. A., and Wilkinson, D. S., 1986b, Psychocutaneous disorders, in: “Textbook of dermatology”, 4th edn., Rook, A., Wilkinson, D. S., Ebling, F. J. G., Champion, R. H., and Burton, J. L., eds., Blackwell Scientific Publications, Oxford.Google Scholar
  96. Rosa, F., 1987, Isotretinoin dose and teratogenicity, Lancet. ii: 1154.CrossRefGoogle Scholar
  97. Rougier, A., and Lotte, C., 1987, Correlations between horny layer concentration and percutaneous absorption, in: “Pharmacology and the skin”, Vol. 1., Shroot, B., and Schaefer, H., eds., Karger, Basel.Google Scholar
  98. Savin, J. A., Dow, R., Harlow, B. J., Massey, H., and Yee, K. F., 1986, The effect of a new non-sedative H1-receptor antagonist (LN2974) on the itching and scratching of patients with atopic eczema, Clin. Exp. Dermatol., 11:600–602.PubMedCrossRefGoogle Scholar
  99. Schaefer, H., 1985, Short-contact therapy, Arch. Dermatol., 121:1505–1509.PubMedCrossRefGoogle Scholar
  100. Schaefer, H., Zesch, A., and Stuttgen, G., 1982, “Skin permeability”, Springer-Verlag, Berlin.CrossRefGoogle Scholar
  101. Schafer-Korting, M., and Korting, H. C., 1989, Skin blisters and skin windows: An access to total and free drug concentrations in the skin, in: “Models in dermatology”, Vol. 4., Maibach, H. I., and Lowe, N. J., eds., Karger, Basel.Google Scholar
  102. Schalla, W., and Schaefer, H., 1987, Pharmacokinetics and topical applications of drugs, in: “Dermatology in general medicine”, 3rd edn., Fitzpatrick, T. B., Eisen, A. Z., Wolff, K., Freedberg, I. M., and Austen, K. F., eds., McGraw-Hill Book Company, New York.Google Scholar
  103. Scheuplein, R. J., 1980, Percutaneous absorption: theoretical aspects, in: “Percutaneous absorption of steroids”, Mauvais-Jarvis, P., Vickers, C. F. H., and Wepierre, J., eds., Academic Press, London.Google Scholar
  104. Scheuplein, R. J., and Bronaugh, R. L., 1983, Percutaneous absorption, in: “Biochemistry and physiology of the skin”, Vol. II., Goldsmith, L. A., ed., Oxford University Press, New York.Google Scholar
  105. Shah, V. P., 1987, Migration of drugs across the skin after oral administration: griseofulvin, in: “Pharmacology and the skin”, Vol. 1., Shroot, B., and Schaefer, H., eds., Karger, Basel.Google Scholar
  106. Sim, A. W., Picton, W., Fox, P. K., and Walker, G. B., 1976, The effect of topical corticosteroids on the metabolism of dermal collagen, in: “Mechanisms of topical corticosteroid activity”, Wilson, L. C., and Marks, R., eds., Churchill Livingstone, Edinburgh.Google Scholar
  107. Singh, G., and Singh, P. K., 1986, Tachyphylaxis to topical steroid measured by histamine-induced wheal suppression, Int. J. Dermatol., 25:324–326.PubMedCrossRefGoogle Scholar
  108. Sorkin, E. M., and Heel, R. C., 1985, Terfenadine — a review of its pharmacodynamic properties and therapeutic efficacy, Drugs. 29: 34–56.PubMedCrossRefGoogle Scholar
  109. Stevanovic, D. V., Wilson, L., and Sparkes, C. G., 1977, A separation of clinical from epidermal thinning effect in the topical glucocorticoid clobetasone butyrate, Br. J. Dermatol., 96:67–70.PubMedCrossRefGoogle Scholar
  110. Stewart, J. C. M., Ferguson, J., and Davey, P., 1983, New antifungal and antiviral chemotherapy, Br. Med. J., 286:1802–1804.CrossRefGoogle Scholar
  111. Sudilovsky, A., Muir, J. G., and Bocobo, F. C., 1981a, Topical corticosteroids. The need (?) for frequent applications, Int. J. Dermatol., 20:594–596.PubMedCrossRefGoogle Scholar
  112. Sudilovsky, A., Muir, J. G., and Bocobo, F. C., 1981b, A comparison of single and multiple applications of halcinonide cream, Int. J. Dermatol., 20:609–613.PubMedCrossRefGoogle Scholar
  113. Sulzberger, M. B., and Witten, V. H., 1952, The effect of topically applied compound F in selected dermatoses, J. Invest. Dermatol., 19:101–102.PubMedGoogle Scholar
  114. Tan, C. Y., Marks, R., and Payne, P., 1981, Comparison of xeroroadiographic and ultrasound detection of corticosteroid induced dermal thinning, J. Invest. Dermatol., 76:126–128.PubMedCrossRefGoogle Scholar
  115. Tan, C. Y., Statham, B., Marks, R., and Payne, P. A., 1982, Skin thickness measurement by pulsed ultrasound: its reproducibility, validation and variability, Br. J. Dermatol., 106:657–667.PubMedGoogle Scholar
  116. Tatnall, F. M., Leigh, I. M., and Gibson, J. R., 1987, Comparative toxicity of antimicrobial agents on transformed human keratinocytes, Br. J. Dermatol., 117(Suppl.32): 31–32.CrossRefGoogle Scholar
  117. Tatnall, F. M., Leigh, I. M., and Gibson, J. R., 1988, A comparative study of antiseptic toxicity on basal keratinocytes, transformed human keratinocytes and fibroblasts, Skin Pharmacol., 1:56.Google Scholar
  118. Tharp, M. D., Kagey-Sobotka, A., Fox, C. C., Marone, G., Lichtenstein, L. M., and Sullivan, T. J., 1987, Functional heterogeneity of human mast cells from different anatomic sites: in vitro responses to morphine sulfate, J. Allergy Clin. Immunol., 79:646–653.PubMedCrossRefGoogle Scholar
  119. Ting, H. C., and Khoo, P. C., 1987, A comparison of topical antibiotic (Fucidin ointment) versus systemic antibiotic (erythromycin) in skin infections, 17th World Congress of Dermatology (Volume of abstracts. Part II). 204.Google Scholar
  120. Voorhees, J. J., 1983, Leukotrienes and other lipoxygenase products in the pathogenesis and therapy of psoriasis and other dermatoses, Arch. Dermatol., 119:541–547.PubMedCrossRefGoogle Scholar
  121. Weinstein, G. D., 1977, Methotrexate, Ann. Intern. Med., 86:199–204.PubMedGoogle Scholar
  122. Wendt, H., and Frosch, P. J., 1982, “Clinico-pharmacological models for the assay of topical corticoids”, Karger, Basel.Google Scholar
  123. White, S. I., Cox, N. H., and MacKie, R. M., 1986, Management of cutaneous fungal disease, Update. 32: 796–803.Google Scholar
  124. Woodford, R., Haigh, J. M., and Barry, B. W., 1983, Possible dosage regimens for topical steroids, assessed by vasoconstrictor assays using multiple applications, Dermatologica. 166:136–140.PubMedCrossRefGoogle Scholar
  125. Woollard, P. M., and Leigh, I., 1987, Stereochemical analysis of 12-hydroxy-5,8,10,14-eicosatetraenoic acid (12-HETE) from adult human epidermal cells in vitro, Br. J. Dermatol., 116:437.Google Scholar
  126. Zheng, P., Lavker, R.M., Lehmann, P., and Kligman, A. M., 1984, Morphologic investigations on the rebound phenomenon after corticosteroidinduced atrophy in human skin, J. Invest. Dermatol., 82:345–352.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1990

Authors and Affiliations

  • John R. Gibson
    • 1
  1. 1.The Wellcome Research LaboratoriesLangley CourtBeckenhamUK

Personalised recommendations